Abstract Number: PB2308
Meeting: ISTH 2020 Congress
Background: Thrombosis of the inferior vena cava (IVC) is a rare form of deep venous thrombosis (DVT). Optimal treatment strategies and clinical outcomes are not well established.
Aims: Compare the baseline characteristics, treatment strategies, and 12-month clinical outcomes of patients with lower extremity DVT (LEDVT) with and without IVC thrombosis enrolled in the Global Anticoagulant Registry in the FIELD – Venous Thromboembolism (GARFIELD-VTE).
Methods: GARFIELD-VTE (ClinicalTrials.gov: NCT02155491) is a global, prospective, non-interventional study of real-world treatment practices. Of the 10,870 patients with objectively confirmed VTE enrolled between May 2014 and January 2017, 7,746 were eligible for analysis in this study.
Results: One-hundred IVC thrombosis patients (all with concomitant LEDVT) and 7,646 LEDVT patients with no IVC involvement were compared. IVC thrombosis patients were younger (51.9 vs. 59.8 years), more frequently had active cancer (23.0% vs. 7.5%) or a history of cancer (21.0% vs. 10.2%), and less frequently had recent trauma or surgery.
At baseline, a higher proportion of patients with IVC thrombosis received thrombolysis (11.3% vs 3.8%) or surgical mechanical interventions (4.1% vs. 1.4%) than those without. Patients with IVC thrombosis more frequently received parenteral anticoagulants alone (37.1% vs. 16.4%), and less frequently received vitamin K antagonists (24.7% vs. 32.2%) or direct oral anticoagulants (± parenteral therapy) (35.0% vs. 48.7%). Treatment duration over 12 months of follow-up was similar (Figure 1). The rate of all-cause mortality was higher in patients with IVC thrombosis (16.6 vs. 6.8 per 100 person-years), however the proportion of cancer-associated deaths was comparable (51.9% vs. 57.1%). Rates of VTE recurrence (4.9 vs. 5.4 per 100 person-years) and bleeding (7.4 vs. 10.3 per 100 person-years) were similar (Table 1).
Conclusions: Patients with IVC thrombosis are younger, and have higher all-cause mortality rates than LEDVT patients, only partly attributable to malignancy.
To cite this abstract in AMA style:Cohen O, Ageno W, Farjat AE, Turpie AGG, Weitz JI, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Dalsgaard Nielsen J, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK, on Behalf of the GARFIELD-VTE Investigators . Management Strategies and Clinical Outcomes in Patients with Inferior Vena Cava Thrombosis: Data from the GARFIELD-VTE Registry [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/management-strategies-and-clinical-outcomes-in-patients-with-inferior-vena-cava-thrombosis-data-from-the-garfield-vte-registry/. Accessed May 20, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/management-strategies-and-clinical-outcomes-in-patients-with-inferior-vena-cava-thrombosis-data-from-the-garfield-vte-registry/